1. Scrip

LOXO-305 Comes Out Swinging In Battle Of BTK Inhibitors

Lilly's Loxo Presents Positive Phase I/II Data In MCL At ASH

 
• By Alaric DeArment

Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.

Digital illustration of Cancer cell in colour background
Loxo Oncology at Lilly announces MCL data from Phase I/II study at ASH • Source: Shutterstock

New data from Loxo Oncology at Lilly has shown that its Bruton’s tyrosine kinase (BTK) inhibitor, LOXO-305, produces high response rates among mantle cell lymphoma (MCL) patients who have previously received older-generation drugs in the same class. But the firm, part of Eli Lilly and Company, has its sights set on a bigger – and riskier – goal: demonstrating superiority over its predecessors.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D